Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis

被引：3
作者：
Townsend, Matthew J. [1 ]
Hodi, F. Stephen [2 ,3 ]
Grover, Shilpa [3 ,4 ]
机构：
[1] Duke Univ Med Ctr, Dept Internal Med, Durham, NC USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA
来源：
ACG CASE REPORTS JOURNAL | 2023年 / 10卷 / 03期
关键词：
immune checkpoint inhibitor; immune-related adverse event; pancreatitis; infliximab; ADVERSE EVENTS;
D O I：
10.14309/crj.0000000000001018
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Acute pancreatitis is an infrequent but clinically significant complication of immune checkpoint inhibitor (ICI) therapy. Guidelines recommend high-dose steroids and withdrawal of ICI in patients with severe ICI-induced pancreatitis. Management of steroid-refractory ICI pancreatitis is unclear. Infliximab is used to treat select extrapancreatic immune-related adverse events, but its role in ICI pancreatitis remains undefined. To our knowledge, we describe the first case of ICI pancreatitis successfully treated with infliximab after inadequate steroid response (recurrent pancreatitis on multiple attempted steroid tapers). Infliximab may be a viable treatment of steroid-refractory ICI pancreatitis. Further study of its potential effectiveness may improve guideline-directed care.
引用
收藏
页数：4
相关论文
共 11 条
  • [1] Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
    Abu-Sbeih, Hamzah
    Tang, Tenglong
    Lu, Yang
    Thirumurthi, Selvi
    Altan, Mehmet
    Jazaeri, Amir A.
    Dadu, Ramona
    Coronel, Emmanuel
    Wang, Yinghong
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [2] [Anonymous], 2017, COMMON TERMINOLOGY C
  • [3] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
  • [4] Understanding and treating the inflammatory adverse events of cancer immunotherapy
    Dougan, Michael
    Luoma, Adrienne M.
    Dougan, Stephanie K.
    Wucherpfennig, Kai W.
    [J]. CELL, 2021, 184 (06) : 1575 - 1588
  • [5] Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis
    George, John
    Bajaj, Divyansh
    Sankaramangalam, Kesavan
    Yoo, Jin Woo
    Joshi, Nikhil S.
    Gettinger, Scott
    Price, Christina
    Farrell, James J.
    [J]. PANCREATOLOGY, 2019, 19 (04) : 587 - 594
  • [6] Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy- A multicentre study of 90 patients from the German Dermatooncology Group
    Grimmelmann, Imke
    Momma, Michael
    Zimmer, Lisa
    Hassel, Jessica C.
    Heinzerling, Lucie
    Pfohler, Claudia
    Loquai, Carmen
    Ruini, Cristel
    Utikal, Jochen
    Thoms, Kai-Martin
    Kaehler, Katharina C.
    Eigentler, Thomas
    Herbst, Rudolf A.
    Meier, Friedegund
    Debus, Dirk
    Berking, Carola
    Kochanek, Corinna
    Ugurel, Selma
    Gutzmer, Ralf
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 149 : 1 - 10
  • [7] Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors
    Shimozaki, Keitaro
    Sukawa, Yasutaka
    Beppu, Noriko
    Kurihara, Isao
    Suzuki, Shigeaki
    Mizuno, Ryuichi
    Funakoshi, Takeru
    Ikemura, Shinnosuke
    Tsugaru, Kai
    Togasaki, Kazuhiro
    Kawasaki, Kenta
    Hirata, Kenro
    Hayashi, Hideyuki
    Hamamoto, Yasuo
    Takaishi, Hiromasa
    Kanai, Takanori
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4585 - 4593
  • [8] Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis
    Su, Qiang
    Zhang, Xiao-chen
    Zhang, Chen-guang
    Hou, Yan-li
    Yao, Yu-xia
    Cao, Bang-wei
    [J]. JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
  • [9] Management of Immunotherapy-Related Toxicities, Version 1.2022
    Thompson, John A.
    Schneider, Bryan J.
    Brahmer, Julie
    Achufusi, Amaka
    Armand, Philippe
    Berkenstock, Meghan K.
    Bhatia, Shailender
    Budde, Lihua E.
    Chokshi, Saurin
    Davies, Marianne
    Elshoury, Amro
    Gesthalter, Yaron
    Hegde, Aparna
    Jain, Michael
    Kaffenberger, Benjamin H.
    Lechner, Melissa G.
    Li, Tianhong
    Marr, Alissa
    McGettigan, Suzanne
    McPherson, Jordan
    Medina, Theresa
    Mohindra, Nisha A.
    Olszanski, Anthony J.
    Oluwole, Olalekan
    Patel, Sandip P.
    Patil, Pradnya
    Reddy, Sunil
    Ryder, Mabel
    Santomasso, Bianca
    Shofer, Scott
    Sosman, Jeffrey A.
    Wang, Yinghong
    Zaha, Vlad G.
    Lyons, Megan
    Dwyer, Mary
    Hang, Lisa
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (04): : 387 - 405
  • [10] Fatal Immune Checkpoint Inhibitor-related Pancreatitis
    Ueno, Masayuki
    Tsuji, Yoshihisa
    Yokoyama, Toshihide
    Koyama, Takashi
    Uenishi, Yosuke
    Ishida, Etsuji
    Mizuno, Motowo
    [J]. INTERNAL MEDICINE, 2021, 60 (24) : 3905 - 3911
12